Top Markets
Coin of the day
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Clasificación en acciones #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Precio por acción
$0.11725176
Última sincronización: 2025-07-14
Capitalización bursátil
$481.50K
Cambio (1 día)
-0.20%
Cambio (1 año)
0.00%
País
FR
Comercio PHAXIAM Therapeutics S.A. (PHXM)

Categoría

Historial del precio de la acción de PHAXIAM Therapeutics S.A. (PHXM)
Precio más alto de cierre: $0.12 el 2025-07-01

Precio más bajo de cierre: $130.13 el 2013-05-01
Historial del precio de la acción de PHAXIAM Therapeutics S.A. desde 2013 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2025 -93.43%
2024 -61.15%
2023 -4.10%
2022 -78.67%
2021 -73.09%
2020 82.18%
2019 -31.14%
2018 -67.04%
2017 59.44%
2016 -51.03%
2015 -15.90%
2014 158.90%
2013 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$517.18 32.51%
US
$857.76 31.47%
NL
$735.86 7.74%
CH
$1.07K -6.40%
KR
$257.99 13.97%
BE